The Motley Fool

Here’s why AstraZeneca shares are a great buy for me

Image source: Getty Images

When I last wrote about AstraZeneca (LSE: AZN) around two months ago, its share price had started inching up after trending downwards for months before that. I had concluded that it would continue to rise. 

The AstraZeneca share price is rising

That is exactly what happened. The AstraZeneca share price has risen 8% since. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

I was expecting this based on a number of reasons. First, there’s its past performance. If I had bought AstraZeneca shares five years ago, I would have seen some neat gains of 114%. But patience is key with this stock. If I had bought it one year ago, I would have barely made any gains. In the interim, the stock actually rose to all-time highs but started sliding down shortly after. 

Approval for new treatment

This kind of short-term fluctuation can get cancelled out for stocks that have inherent value to them. And there is indeed value to the AstraZeneca share. 

Just earlier today, the company announced new forays. Its lung cancer treatment, developed with the Hong Kong-based Hutchmed, has been approved by China, which accounts for a third of lung cancer patients. Another of the Anglo-Swedish company’s treatments for lung cancer was approved by the European Union (EU) last month.

End to vaccine woes

After some confusion over whether or not it was effective, two separate studies have shown that AstraZeneca’s Covid-19 vaccine is indeed effective against variants. Even though the company has always maintained that it does not intend to make profits from the vaccine developed with the University of Oxford, there is a reputational advantage to providing effective vaccination. 

In another article today, I talk about the case of GlaxoSmithKline in this regard. While it announced last year that it will develop a Covid-19 vaccine along with the French pharmaceutical company Sanofi, it is still in progress. As a result, it has missed out on the initial vaccination push. The company’s share price has tumbled over the past year. While this is due to several reasons, I think slow vaccine development may have disappointed investors too. 

Coming back to AstraZeneca, vaccine effectiveness has not been its only challenge in recent months. The company has also suffered some damage recently from its friction with the EU over delivery of the vaccines. However, a court ruling has provided some relief to the pharmaceuticals biggie. The EU wanted it to deliver vaccines in a hurry or pay a huge fine. The court has not mandated this for AstraZeneca. 

What I’d do now

So things appear to be falling in place once again for AstraZeneca. The EU issue is partly resolved, its vaccine is effective, and its new treatments are being approved. Its financial performance is already strong. At the same time, its current share price is far lower than it was at last year’s high points. I think it can gain further from here. I’m thinking of adding to my holding of AstraZeneca shares. 

There’s a ‘double agent’ hiding in the FTSE… we recommend you buy it!

Don’t miss our special stock presentation.

It contains details of a UK-listed company our Motley Fool UK analysts are extremely enthusiastic about.

They think it’s offering an incredible opportunity to grow your wealth over the long term – at its current price – regardless of what happens in the wider market.

That’s why they’re referring to it as the FTSE’s ‘double agent’.

Because they believe it’s working both with the market… And against it.

To find out why we think you should add it to your portfolio today…

Click here to get access to our presentation, and learn how to get the name of this 'double agent'!

Manika Premsingh owns shares of AstraZeneca. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.